Intellia Therapeutics, Inc. (NASDAQ:NTLA) Shares Purchased by Wells Fargo & Company MN

Wells Fargo & Company MN lifted its stake in shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA - Free Report) by 38.3% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 277,692 shares of the company's stock after purchasing an additional 76,872 shares during the quarter. Wells Fargo & Company MN owned about 0.27% of Intellia Therapeutics worth $3,238,000 at the end of the most recent quarter.

Other hedge funds have also recently modified their holdings of the company. Whipplewood Advisors LLC acquired a new position in Intellia Therapeutics in the 4th quarter valued at $40,000. Resona Asset Management Co. Ltd. acquired a new position in shares of Intellia Therapeutics during the fourth quarter worth about $43,000. Jones Financial Companies Lllp increased its stake in shares of Intellia Therapeutics by 140.9% during the fourth quarter. Jones Financial Companies Lllp now owns 3,898 shares of the company's stock worth $45,000 after acquiring an additional 2,280 shares during the period. Daiwa Securities Group Inc. raised its holdings in Intellia Therapeutics by 80.6% during the fourth quarter. Daiwa Securities Group Inc. now owns 5,151 shares of the company's stock worth $60,000 after purchasing an additional 2,299 shares in the last quarter. Finally, KBC Group NV lifted its position in Intellia Therapeutics by 62.4% in the fourth quarter. KBC Group NV now owns 6,093 shares of the company's stock valued at $71,000 after purchasing an additional 2,340 shares during the period. 88.77% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on NTLA. Wells Fargo & Company cut their target price on Intellia Therapeutics from $60.00 to $50.00 and set an "overweight" rating for the company in a research note on Friday, February 28th. JPMorgan Chase & Co. reiterated a "neutral" rating and issued a $13.00 price objective (down previously from $45.00) on shares of Intellia Therapeutics in a research report on Friday, February 28th. Truist Financial decreased their target price on shares of Intellia Therapeutics from $90.00 to $50.00 and set a "buy" rating on the stock in a research report on Tuesday, March 4th. Barclays cut their price target on shares of Intellia Therapeutics from $55.00 to $26.00 and set an "overweight" rating for the company in a report on Friday, February 28th. Finally, Wolfe Research raised shares of Intellia Therapeutics from a "peer perform" rating to an "outperform" rating and set a $21.00 price objective on the stock in a report on Monday, April 21st. Two equities research analysts have rated the stock with a sell rating, six have given a hold rating, twelve have given a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average price target of $36.68.

Intellia Therapeutics Trading Up 2.0 %

Shares of NASDAQ:NTLA traded up $0.17 on Monday, hitting $8.48. The company had a trading volume of 3,140,582 shares, compared to its average volume of 2,388,955. The company has a market cap of $877.82 million, a PE ratio of -1.56 and a beta of 2.23. The business has a 50 day moving average of $8.59 and a 200 day moving average of $11.70. Intellia Therapeutics, Inc. has a 52-week low of $5.90 and a 52-week high of $28.18.

Intellia Therapeutics Profile

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.